Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
IL-17 inhibitors
10 evidence topics · 10 sources
Biologics guideline: recommendations for secukinumab, ixekizumab, and brodalumab, and inflammatory bowel disease
Secukinumab: FDA-approved indication, dosage, and week 12 outcomes in Trials PsO1 and PsO2
| Outcome at Week 12, Trial PsO1, n (%) | COSENTYX 300 mg (N = 245) | COSENTYX 150 mg (N = 245) | Placebo (N = 248) |
|---|---|---|---|
| PASI 75 response | “200 (82)” | “174 (71)” | “11 (4)” |
| IGA of clear or almost clear | “160 (65)” | “125 (51)” | “6 (2)” |
Ixekizumab: FDA-approved indication, dosage, and week 12 outcomes in Trial 1
| Outcome at Week 12, Trial 1, n (%) | TALTZ 80 mg Q2W (N=433) | Placebo (N=431) |
|---|---|---|
| sPGA of 0 (clear) or 1 (minimal) | “354 (82)” | “14 (3)” |
| PASI 90 | “307 (71)” | “2 (1)” |
| PASI 100 | “153 (35)” | “0” |
Brodalumab: boxed warning for suicidal ideation and behavior, REMS, restricted indication, and dosage
Brodalumab versus ustekinumab and placebo: week 12 outcomes in Trial 2
| Outcome at Week 12, Trial 2, n (%) | SILIQ 210 mg Q2W (N=612) | Ustekinumab (N=300) | Placebo (N=309) |
|---|---|---|---|
| PASI 75 response | “528 (86)” | “210 (70)” | “25 (8)” |
| PASI 100 response | “272 (44)” | “65 (22)” | “2 (1)” |
Bimekizumab: FDA-approved indication, dosage, suicidal ideation warning, and week 16 outcomes
| Outcome at Week 16, n (%) | Trial Ps-1 BIMZELX 320 mg every 4 weeks (N=321) | Trial Ps-1 placebo (N=83) | Trial Ps-2 BIMZELX 320 mg every 4 weeks (N=349) | Trial Ps-2 placebo (N=86) |
|---|---|---|---|---|
| IGA 0 or 1 | “270 (84%)” | “4 (5%)” | “323 (93%)” | “1 (1%)” |
| PASI 90 | “273 (85%)” | “4 (5%)” | “317 (91%)” | “1 (1%)” |
| PASI 100 | “188 (59%)” | “0 (0%)” | “238 (68%)” | “1 (1%)” |
BE RADIANT: bimekizumab versus secukinumab, PASI 100 at weeks 16 and 48 and oral candidiasis
“A total of 1005 patients were screened and 743 were enrolled; 373 patients were assigned to receive bimekizumab and 370 to receive secukinumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, a total of 230 patients (61.7%) in the bimekizumab group and 181 (48.9%) in the secukinumab group had a 100% reduction from baseline in the PASI score (PASI 100) (adjusted risk difference, 12.7 percentage points; 95% confidence interval [CI], 5.8 to 19.6); bimekizumab was shown to be noninferior and superior to secukinumab (P<0.001 for noninferiority and superiority).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 48, a total of 250 patients (67.0%) treated with bimekizumab had a PASI 100 response, as compared with 171 patients (46.2%) treated with secukinumab (adjusted risk difference, 20.9 percentage points; 95% CI, 14.1 to 27.7; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Oral candidiasis occurred more often with bimekizumab (72 patients, 19.3%) than with secukinumab (11 patients, 3.0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(Funded by UCB Pharma; BE RADIANT ClinicalTrials.gov number, NCT03536884.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements: bimekizumab safety profile and candidiasis
“In the opinion of the guideline group, bimekizumab has, with the exception of candidiasis, a similar safety profile to other IL‐17 antagonists, such as ixekizumab and secukinumab, as well as the IL‐17R antagonist brodalumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Infections: The three most common TEAEs were nasopharyngitis (19.1 per 100 person‐years; 95% CI 17.4–20.9 per 100 person‐years), oral candidiasis (12.6 per 100 person‐years; 95% CI 11.3–14.0 per 100 person‐years), and infections of the upper respiratory tract (8.9 per 100 person‐years; 95% CI 7.8–10.1 per 100 person‐years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dual inhibition of IL‐17A and IL‐17F may impair the protective function of mucous membranes more strongly, thus increasing the risk of oral candidiasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Decision aid: IL-17 inhibitors
| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
|---|---|---|
| Bimekizumab | “54%” | “Not known at present” |
| Brodalumab | “50%” | “Not known at present” |
| Ixekizumab | “53%” | “77–83% chance” |
| Secukinumab | “47%” | “80–83% chance” |
Network meta-analysis: anti-IL-17 agents compared with placebo and with other classes
“In terms of reaching PASI 90, anti‐IL17 treatments (secukinumab, ixekizumab, izokibep, brodalumab, bimekizumab, sonelokimab, and xeligekimab) were more effective than placebo (class‐level RR 27.19, 95% CI 19.49 to 37.92).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At class level, anti‐IL17 treatment showed a higher proportion of participants reaching PASI 90 compared to all the interventions versus anti‐IL23 (RR 1.15, 95% CI 1.01 to 1.31); versus anti‐IL12/23 (RR 1.44, 95% CI 1.27 to 1.64); versus anti‐TNF‐alpha (RR 1.92, 95% CI 1.68 to 2.19); versus TYK‐2 inhibitors (RR 3.20, 95% CI 2.08 to 4.94); versus non‐targeted systemic treatments (RR 4.01, 95% CI 2.65 to 6.05); and versus phosphodiesterase‐4 inhibitors (RR 5.82, 95% CI 3.95 to 8.58) (Supplementary material 15).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of a difference in favour of bimekizumab, ixekizumab, and risankizumab compared to secukinumab in terms of achieving PASI 90.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
|---|---|---|---|
| Ixekizumab, 80 mg | “88.8 (86.5-90.9)”View highlighted excerpt for this quote | “70.8 (66.8-74.6)”View highlighted excerpt for this quote | “39.5 (35.2-44.0)”View highlighted excerpt for this quote |
| Brodalumab, 210 mg | “88.7 (86.5-90.8)”View highlighted excerpt for this quote | “70.6 (66.8-74.6)”View highlighted excerpt for this quote | “39.2 (35.2-43.9)”View highlighted excerpt for this quote |
| Secukinumab, 300 mg | “83.1 (80.2-85.7)”View highlighted excerpt for this quote | “61.4 (57.2-65.6)”View highlighted excerpt for this quote | “29.9 (26.3-33.9)”View highlighted excerpt for this quote |